Volume 31, Number 3—March 2025
Synopsis
Candida auris Outbreak and Epidemiologic Response in Burn Intensive Care Unit, Illinois, USA, 2021–2023
Table
Characteristics of 28 Candida auris outbreak case-patients in BICU, Illinois, USA, 2021–2023*
Characteristic | Value |
---|---|
Sex | |
F | 13 (46) |
M |
15 (54) |
Average age, y (range) |
49 (16–81) |
Admission diagnosis | |
Burn | 18 (64) |
Soft tissue infection not including burns | 9 (32) |
COVID-19† |
1 (4) |
C. auris culture source | |
Axillary/inguinal screening culture‡ | 24 (86) |
Clinical culture§ | 14 (50) |
Blood | 8 (29) |
Respiratory | 6 (21) |
Wound | 8 (29) |
Urine |
3 (11) |
Co-infection with multidrug-resistant organism¶ |
13 (46) |
Mean length of stay from admission to first positive C. auris culture, d (range) |
26 (7–83) |
Recent hospitalization <1 month before hospitalization |
8 (29) |
Medical devices used <1 week before positive C. auris culture | |
Central venous catheter | 24 (86) |
Ventilator | 18 (64) |
Urinary catheter |
24 (86) |
Ancillary medical services received <1 week before first positive C. auris culture | |
Occupational therapy | 23 (82) |
Physical therapy | 18 (64) |
Speech therapy |
5 (18) |
Mean length of stay in BICU, d (range) |
67 (6–442) |
C. auris outcome | |
Colonization | 14 (50) |
Infection |
13 (46) |
Discharge disposition | |
Skilled nursing facility, acute rehab or other hospital | 17 (61) |
Home | 5 (18) |
Deceased | 6 (21) |
*Values are no. (%) except as indicated. BICU, burn intensive care unit. †Medical intensive care unit service patient on overflow to BICU. ‡Ten of the 24 patients with a positive axillary/inguinal screen also had C. auris identified from a clinical culture. §Of the clinical cultures, 4 patients had C. auris identified only in blood, 3 had C. auris only from wound infections, 1 had C. auris only from respiratory source, and the remaining 6 had C. auris identified in >1 clinical culture source. ¶A total of 13 patients were co-infected or co-colonized with 19 other multidrug-resistant organisms: 6 vancomycin-resistant enterococci, 5 extended-spectrum β-lactamase–producing organisms, 3 methicillin-resistant Staphylococcus aureus, 2 multidrug-resistant Pseudomonas aeruginosa (MDR-PA), 1 carbapenem-resistant Acinetobacter baumannii, 1 carbapenem-resistant Enterobacterales, 1 AmpC β-lactamase–producing organism.
1These first authors contributed equally to this article.
2These authors contributed equally to this article.